Plain-English translation of NCT07527910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help reduce the amount of fat in your liver. The study will test this medication alone and also combined with , a drug commonly used to help control blood sugar and weight. Researchers want to learn whether this treatment works better on its own or when paired with the other medication.
Fatty liver disease caused by a specific genetic change is a serious condition that can lead to liver damage over time, and there are currently very limited treatment options available. This medication is designed to target the underlying genetic problem, so this trial aims to find out if it can actually reduce liver fat and help protect people's health.
You likely qualify if…
You likely don't qualify if…
The study is split into two parts. In Part A, you would already be taking , and researchers would randomly assign you to either receive or a placebo to see how it works. In Part B, you would start by taking the study medication and may or may not also receive . You would visit the clinic multiple times over the course of the study, have blood tests and MRI scans to measure how much fat is in your liver, and report any side effects you experience.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States